Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. 2013

Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.

BACKGROUND To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases. METHODS We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer. RESULTS Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted. CONCLUSIONS mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
January 2019, Cancer control : journal of the Moffitt Cancer Center,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
June 2015, Hepato-gastroenterology,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
January 2014, Japanese clinical medicine,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
April 2008, Gan to kagaku ryoho. Cancer & chemotherapy,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
November 2009, Gan to kagaku ryoho. Cancer & chemotherapy,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
January 2011, Hepato-gastroenterology,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
December 2023, Anticancer research,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
April 2010, The Canadian journal of urology,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
December 2012, Gan to kagaku ryoho. Cancer & chemotherapy,
Yutaka Yanagihara, and Nozomu Tanji, and Noriyoshi Miura, and Akitomi Shirato, and Kenichi Nishimura, and Tetsuya Fukumoto, and Koji Azuma, and Yuki Miyauchi, and Tadahiko Kikugawa, and Masayoshi Yokoyama
April 2020, International journal of clinical oncology,
Copied contents to your clipboard!